These NLRP3 inhibitors are more effective than IL-1β inhibitors in mouse models of CAPS, suggesting that inactivating the inflammasome directly will provide greater therapeutic value than targeting downstream released cytokines such as IL-1β. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.